Takeda Pharmaceutical Company Limited

Takeda Chemical Industries, Inc.

Tomohiro Kaku

Mitsuhiro Ito

Shigemitsu Matsumoto

Yasushi Hattori

Takuto Kojima

Masashi Toyofuku

Shinji Morimoto

Masaki Daini

Akihiro Tasaka

Masami Kusaka

Masuo Yamaoka

Akio Ojida

Norihito Tokunaga

Yuya Oguro

Masaki Ogino

Shizuo Kasai

Eiji Kimura

Taku Kamei

Takeshi Wakabayashi

Masahiro Kamaura

Yasuhisa Kohara

Tomoko Ohashi

Daisuke Tomita

Shinichi Imamura

Tetsuya Aono

Shohei Hashiguchi

Yusuke Tominari

Fumio Itoh

Naoki Tomita

Yoshi Nara

Noritaka Kuroda

Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Heterocyclic compound

The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Cyclopropanamine compound and use thereof

The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof. 

The present invention provides a compound having a lysine specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's disease, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s);

The present invention relates to wherein each symbol is as defined in the specification. The compound of the present invention has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of disease and condition mediated by increased RBP4.

A composition containing a compound of the formula: wherein A is a nitrogen-containing heterocyclic group which may be substituted, Ris a hydrogen atom, hydrocarbon group which may be substituted, or monocyclic aromatic heterocyclic group which may be substituted, Ris a hydrogen atom or a lower alkyl group which may be substituted, R, R, R, R, R, Rand Rare independently a hydrogen atom, a hydrocarbon group which may be substituted, a hydroxy group which may be substituted, a thiol group which may be substituted, an amino group which may be substituted, an acyl group or a halogen atom, a salt thereof or a prodrug thereof has steroid C-lyase inhibitory activity, and are useful for preventing and treating a mammal suffering from, for example, primary cancer of malignant tumor, its metastasis and recurrence thereof.

Naphthalene derivatives, their production and use

The present invention provides a pharmaceutical composition having a steroid C-lyase inhibitory activity, which is useful as a prophylactic or therapeutic agent of prostatism, tumor such as breast cancer and the like, more particularly, a steroid C-lyase inhibitor containing a compound represented by the formula: wherein Ais an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, one of Aand Ais a hydrogen atom, a halogen atom, a Caliphatic hydrocarbon group optionally having substituents or an optionally esterified carboxyl group, the other of Aand Ais an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, and at least one of A, Aand Ais a 3-pyridyl group optionally having substituents, or a salt thereof or a prodrug thereof.

Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof

Imidazol-4-ylmethanols and their uses for preventing and treating primary tumors, metastasis and recurrence of tumors, various symptoms accompanying tumors, prostatic hypertrophy, virilism, hirsutism, male pattern alopecia, precocious puberty, endometriosis, uterine myoma, mastopathy and polycystic ovary syndrome are disclosed.

Imidazol-4-ylmehanols and their use as inhibitors of steroid C17-20 lyase

Growing community of inventors

Kanagawa, Japan

Tomohiro Kaku